Edition:
United Kingdom

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
19 Oct 2018
Change (% chg)

$0.01 (+1.84%)
Prev Close
$0.55
Open
$0.56
Day's High
$0.63
Day's Low
$0.54
Volume
38,556
Avg. Vol
62,173
52-wk High
$6.08
52-wk Low
$0.49

Chart for

About

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $48.36
Shares Outstanding(Mil.): 78.00
Dividend: --
Yield (%): --

Financials

  CTRV.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -0.29 -- --
ROI: -126.93 0.21 14.27
ROE: -- 1.17 15.99

BRIEF-Contravir Pharma Files For Series C Convertible Preferred Stock

* CONTRAVIR PHARMACEUTICALS FILES FOR SERIES C CONVERTIBLE PREFERRED STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2wUNyv5) Further company coverage:

18 May 2018

Earnings vs. Estimates